Cantor Fitzgerald Brokers Cut Earnings Estimates for PRQR

ProQR Therapeutics (NASDAQ:PRQR) – Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of ProQR Therapeutics in a research report issued to clients and investors on Monday, May 12th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the biopharmaceutical company will earn ($0.43) per share for the year, down from their prior estimate of ($0.39). Cantor Fitzgerald has a “Overweight” rating and a $8.00 price objective on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.90 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%.

A number of other brokerages also recently weighed in on PRQR. HC Wainwright lifted their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, March 14th. Evercore ISI initiated coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an “outperform” rating and a $5.00 price target for the company. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Monday, March 10th. Chardan Capital restated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday, March 14th. Finally, Oppenheimer dropped their price target on ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

ProQR Therapeutics Trading Down 3.8%

PRQR stock opened at $1.53 on Wednesday. The firm has a market cap of $160.98 million, a PE ratio of -4.78 and a beta of 0.35. The stock has a 50-day moving average price of $1.48 and a 200-day moving average price of $2.37. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $4.62.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its stake in ProQR Therapeutics by 11.8% during the 4th quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 8,621 shares during the last quarter. Jane Street Group LLC purchased a new stake in ProQR Therapeutics in the 4th quarter valued at $30,000. Squarepoint Ops LLC boosted its holdings in ProQR Therapeutics by 16.3% during the 4th quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 11,623 shares during the last quarter. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth $32,000. Finally, OneDigital Investment Advisors LLC raised its holdings in shares of ProQR Therapeutics by 45.5% in the first quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 12,500 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).